Related Experiment Videos

Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure

Toru Kinugawa1, Masahiko Kato, Kazuhide Ogino

  • 1Department of Cardiovascular Medicine, Tottori University Faculty of Medicine, Yonago, Japan.

Journal of Cardiac Failure
|September 19, 2003
PubMed

Insights

Elevated endothelin-1 (ET-1) levels in chronic heart failure (CHF) patients are linked to disease severity. Maximal exercise does not impact ET-1 levels, but peak oxygen uptake and BNP are independently associated with resting ET-1.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pulmonology

Background:

  • Endothelin-1 (ET-1) is a potent vasoconstrictor peptide.
  • Elevated plasma ET-1 levels are observed in patients with chronic heart failure (CHF).

Purpose of the Study:

  • To investigate the relationship between plasma ET-1 levels and clinical correlates in CHF patients.
  • To examine the effects of maximal exercise on plasma ET-1 levels in CHF.

Main Methods:

  • Measured plasma concentrations of ET-1, norepinephrine, atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP) at rest and post-exercise.
  • Included 100 CHF patients (NYHA class I-III) and 27 controls.

Main Results:

  • NYHA class II and III CHF patients exhibited higher ET-1 levels compared to controls and NYHA class I.
  • Maximal exercise did not alter ET-1 levels in any group.
  • Univariate analysis showed relationships between resting ET-1 and cardiothoracic ratio, peak VO2, norepinephrine, ANP, and BNP.
  • Multivariate analysis identified peak VO2 and plasma BNP as independently associated with resting ET-1 levels.

Conclusions:

  • Resting ET-1 levels are elevated in symptomatic CHF patients.
  • Maximal exercise does not affect ET-1 levels in CHF.
  • Peak VO2 and plasma BNP are independently associated with resting ET-1 levels in CHF.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...